Roche, Spark extend $4.3 billion takeover again, this time to September 3

Roche and Spark Therapeutics announced another extension of the Swiss drugmaker's $4.3 billion takeover offer for the U.S. gene therapy specialist as regulatory reviews in the United States and Britain continue.